1
May 2026
Identifying the ages when Alzheimer’s biomarkers sharply change
New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding neurodegeneration across the aging spectrum.

The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow etc., the economic value needs to be demonstrated to healthcare payers.
Using Health Technology Assessment, the value of a novel medical intervention is quantified by simultaneous analysis of effects on patient outcomes and total costs of care associated with the innovation in comparison to the standard of care. An objective measure of the medical innovation’s value is generally required for (national) reimbursement applications.
Mercury Pharmaceuticals offers tailor-made Health Technology Assessment expertise through:

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
1
May 2026
New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding neurodegeneration across the aging spectrum.
1
May 2026
While AI scribes reduce documentation time, their effect on after-hours work is minimal, highlighting the need for further studies on clinician productivity.
1
May 2026
The study links facial aging rates to cancer outcomes, suggesting a new prognostic tool that could personalize treatment and enhance patient survival.
30
Apr 2026
Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.